Satavaptan

Satavaptan
Systematic (IUPAC) name
N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 185913-78-4
ATC code None
PubChem CID 9810773
UNII AJS8S3P31H Y
Chemical data
Formula C33H45N3O8S 
Mol. mass 643.789
 Y(what is this?)  (verify)

Satavaptan (INN; codenamed SR121463, planned tradename Aquilda) is a vasopressin-2 receptor antagonist[1] undergoing research for the treatment of hyponatremia. It is also being studied for the treatment of ascites.[2]

It was developed by Sanofi-Aventis. As of 2008, it is under regulatory review in the European Union.

References

  1. ^ Soupart A, Gross P, Legros JJ et al. (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clin J Am Soc Nephrol 1 (6): 1154–1160. doi:10.2215/CJN.00160106. PMID 17699341. 
  2. ^ Ginès P, Wong F, Watson H, Milutinovic S, Ruiz Del Arbol L, Olteanu D (February 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial". Hepatology 48 (1): 204–213. doi:10.1002/hep.22293. PMID 18508290. 
Sulfonamides
(except EA)
Thiazide-likes (primarily DCT)
Potassium-sparing (at CD)
Osmotic diuretics (PT, DL)
VAs (DCT and CD)
Other

M: VAS

anat(a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot

noco/syva/cong/lyvd/tumr, sysi/epon, injr

proc, drug(C2s+n/3/4/5/7/8/9)